Abstracts tagged "T Cell"

Abstract Number: 0086 • ACR Convergence 2023
Optimizing PD-1 Agonist Signaling with Membrane Proximal Binding of Rosnilimab, a Clinical Stage PD-1 Agonist IgG1 Antibody
Stephen Parmley, Benjamin Szylyk, Richard Frank, Matthew Hsu, Polina Brodsky, Cailin Sibley, Paul Lizzul and Martin Dahl, AnaptysBio, San Diego, CA
Background/Purpose: Checkpoint antagonist therapeutics have transformed the field of oncology while advancing the understanding of adequate checkpoint activity in preventing autoimmunity. Checkpoint agonism represents a…
Abstract Number: 0699 • ACR Convergence 2023
T Cell Subset Analysis in Patients with Large-Vessel Vasculitis
Rebecca Kuan¹, Christopher Redmond¹, McKella Sylvester², Mary Maclean¹, Francoise Meylan¹, Marcela Ferrada¹, Kaitlin Quinn¹ and Peter Grayson³, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²Colgate University, Bethesda, MD, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: Large-vessel vasculitis (LVV) is characterized by granulomatous inflammation of the aorta and its major branches. The two major forms are giant cell arteritis (GCA)…
Abstract Number: 1311 • ACR Convergence 2023
T Cell Subset Signatures Predicted Clinical Response to Etanercept-biosimilar Yisaipu in Patients with Rheumatoid Arthritis
Huaqun Zhu¹, Sumei Tang¹, Gong Cheng¹, Yingni Li¹, Yun Li¹, Feng Sun¹, Xiaolin Sun¹, Jiahui Cheng¹, Ru Li¹ and Zhanguo Li², ¹Peking University People’s Hospital, Beijing, China, ²Peking University Health Science Center, Department of Rheumatology and Immunology, People's Hospital, Beijing, China
Background/Purpose: Our study aimed to use machine-learning approaches to characterize the immune cell profiles of patients who were inadequate responders to Etanercept-Biosimilar Yisaipu (Yisaipu-IRs) and…
Abstract Number: 2331 • ACR Convergence 2023
Molecular Predictors of Treatment Response in Two Trials of Abatacept in Systemic Lupus Erythematosus
Kevin Thomas¹, Miles Smith¹, Carla Guthridge¹, Nicolas Dominguez¹, Susan Macwana¹, Wade DeJager¹, Catriona Wagner¹, Peter Schafer², Stan Kamp¹, Betty Diamond³, David Wofsy⁴, Aikaterini Thanou⁵, Cristina Arriens⁶, Cynthia Aranow³, Joan Merrill¹, Judith James¹ and Joel Guthridge¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Bristol Myers Squibb, Belle Mead, NJ, ³Feinstein Institutes for Medical Research, Manhasset, NY, ⁴University of California San Francisco, San Francisco, CA, ⁵University of Oklahoma Health, Edmond, OK, ⁶Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Department of Arthritis & Clinical Immunology, Oklahoma City, OK
Background/Purpose: Abatacept (ABA) is a fusion protein that disrupts T cell co-stimulation by inhibiting interactions between CD28 and CD80/86. ABA is effective in RA, but…
Abstract Number: 0067 • ACR Convergence 2023
Dimethyl Fumarate Modulates T Cell Metabolism and Function in Systemic Lupus Erythematosus Patient Samples
Loren Kell¹, Samuel Taylor², Kavina Shah², Roel De Maeyer², Debajit Sen², Madhura Castelino², Jo Cambridge², David Isenberg², Maria Leandro³, Arne Akbar² and venkat Reddy², ¹University College London, Oxford, United Kingdom, ²University College London, London, United Kingdom, ³University College London/UCLH, London, United Kingdom
Background/Purpose: Activated T cells make a significant contribution to inflammation in systemic lupus erythematosus (SLE). We know that cellular metabolism regulates the activation of T…
Abstract Number: 0087 • ACR Convergence 2023
Immune Checkpoint Inhibitor Therapy Expands an Activated, anti-PD-1 Drug-bound CD8 T Cell Population That Is Clonally Linked in Blood and Synovial Fluid of ICI-arthritis Patients
Kathryne Marks¹, Anvita Singaraju², Runci Wang³, Ifeoluwakiisi Adejoorin¹, Miriam Fein², Michael Postow⁴, Karmela Kim Chan², Anne Bass⁵, Laura Donlin² and Deepak Rao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Hospital for Special Surgery, New York, NY, ³Renji hospital, Shanghai Jiaotong University, Pudong Xinqu, China, ⁴Memorial Sloan Kettering Cancer Center, New York, NY, ⁵Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Immune checkpoint inhibitor (ICI) therapies used to treat cancer can induce immune related Adverse events (irAEs) such as ICI-induced arthritis (ICI-arthritis). We have previously…
Abstract Number: 0778 • ACR Convergence 2023
The Effect of Probiotic Modulation of Enteral Dysbiosis on Disease Activity in Patients with Psoriatic Arthritis – A Randomized Controlled Trial
Anirudh Subramanian Muralikrishnan¹, Barbara Dreo², Angelika Lackner¹, Rusmir Husic³, Florentine Moazedi-Fuerst³, Josef Hermann⁴, Philipp Bosch¹, Johannes Fessler¹, Jens Thiel⁵ and Martin Stradner¹, ¹Medical University of Graz, Graz, Austria, ²Division of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ³Meduni Graz, Graz, Austria, ⁴Division of Rheumatology and Immunology, Department of Internal Medicine, Medical University Graz, Graz, Austria, ⁵University Hospital Freiburg, Freiburg, Germany
Background/Purpose: Psoriatic Arthritis (PsA) is a painful disease of the joints and spine. Recent studies have described enteric dysbiosis as a possible pathological mechanism in…
Abstract Number: 1339 • ACR Convergence 2023
Neutrophil Activation and Formation of Neutrophil Extracellular Traps Are Associated with Response to Abatacept in Patients with Moderate to Severe Rheumatoid Arthritis
Ting Wang¹, Natalia V. Giltiay², Christian Lood² and Bobby Kwanghoon Han², ¹University of Washington, Seattle, WA, ²Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Neutrophil activation and formation of neutrophil extracellular traps (NETs) have been implicated in the pathogenesis of rheumatoid arthritis (RA). Calprotectin, a neutrophil activation marker,…
Abstract Number: 2439 • ACR Convergence 2023
Proteomic and Genomic Profiling of Plasma Exosomes from Ankylosing Spondylitis Patients
Fataneh Tavasolian¹, starlee lively², Chiara Pastrello³, Michael Tang², Melissa Lim², Addison Pacheco², Zoya Qaiyum², Enoch Yau², Zeynep Baskurt⁴, Igor Jurisica⁵, Mohit Kapoor⁶ and Robert Inman², ¹Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Osteoarthritis Research Program, Division of Orthopaedic Surgery, Schroeder Arthritis Institute and Data Science Discovery Centre for Chronic diseases, Krembil Research Institute, Toronto, ON, Canada, ⁴Department of Biostatistics, University Health Network, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute and Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, ⁶Division of Orthopaedics, Osteoarthritis Research Program, Schroeder Arthritis Institute, and Krembil Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Recent advances in understanding the biology of Ankylosing Spondylitis (AS) using innovative genomic and proteomic approaches offer the opportunity to address current challenges in…
Abstract Number: 0069 • ACR Convergence 2023
All-trans Retinoic Acid (atRA) Enhances FoxP3 Protein Stability Under Inflammatory Conditions Through Altering the FoxP3 Protein-interactome
William Willis¹, shane Bruckner² and wael Jarjour², ¹Ohio State University, Reynoldsburg, OH, ²Ohio State University, Columbus, OH
Background/Purpose: Treg cells play a central role in the tolerance of self-antigens and prevention of autoimmune disease. FoxP3 is a Treg-specific transcription factor that plays…
Abstract Number: 0088 • ACR Convergence 2023
SLAMF4 Orchestrates the Pathological Cytotoxic Response of CD4+ T Cells in Rheumatoid Arthritis
Megane Lacaud¹, Houda-Ghozlane Bouzidi¹, Magali breckler¹, Delphine Lemeiter², Luca Semerano³, Marie-Christophe Boissier³, Natacha Bessis⁴ and Jerome Biton², ¹Inserm UMR 1225, Université Sorbonne Paris Nord, Bobigny, France, ²Inserm UMR 1125, Université Sorbonne Paris Nord, Bobigny, France, ³Inserm UMR 1125, Université Sorbonne Paris Nord; Assistance Publique-Hôpitaux de Paris, Rheumatology department, Avicenne Hospital, Bobigny, France, ⁴Inserm UMR 1125, Université Sorbonne Paris Nord, Bobigny, France
Background/Purpose: CD4+ Foxp3- conventional T cells (Tconv) play a key role in the inflammatory process involved in rheumatoid arthritis (RA). Recent studies, aided by a…
Abstract Number: 0799 • ACR Convergence 2023
Human Chimeric Antigen Receptor (CAR)-Tregs Targeting OX40L for Treatment of Systemic Lupus Erythematosus
Holly Wobma¹, Xianliang Rui², Francesca Alvarez-Calderon², Ulrike Gerdemann², Connor McGuckin², Bruce Blazar³, Victor Tkachev⁴ and Leslie Kean², ¹Division of Immunology, Boston Children's Hospital, Boston, MA, ²Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA, ³Division of Pediatric Blood & Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, MN, ⁴Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA
Background/Purpose: Chimeric Antigen Receptor Regulatory T cells (CAR-Tregs) are an emerging strategy to restore immune tolerance during auto- or allo-immune conditions. However, most autoimmune diseases…
Abstract Number: 1366 • ACR Convergence 2023
A Unique Cluster of Inflammatory Monocytes and Functionally Intact Regulatory T Cells in Rare Childhood Sjögren’s Disease
Myung-Chul Kim¹, Umasankar De², Nicholas Borcherding³, Joon Paek⁴, Nicole Winn⁵, Indraneel Bhattacharyya⁶, Qing Yu⁷, Ryan Kolb⁸, Theodore Drashansky⁹, Akaluck Thatayatikom¹⁰, Weizhou Zhang⁸ and Seunghee Cha¹¹, ¹Jeju National University, Jeju-si, South Korea, ²University of Florida, Gainesville, FL, ³Washington University School of Medicine in St. Louis, Washington, DC, ⁴Department of Oral & Maxillofacial Diagnostic Sciences, Gainesville, FL, ⁵Division of Oral Medicine, Department of Oral and Maxillofacial Diagnostic Sciences, University of Florida College of Dentistry, Gainesville, FL, ⁶Department of Oral & Maxillofacial Diagnostic Sciences, University of Florida College of Dentistry, Gainesville, FL, ⁷The Forsyth Institute, Cambridge, MA, ⁸Department of Pathology & Immunology, University of Florida, Gainesville, FL, ⁹Cellularity, Inc, Florham Park, NJ, ¹⁰AdventHealth for Children, Orlando, FL, Orlando, FL, ¹¹Department of Oral & Maxillofacial Diagnostic Sciences, University of Florida College of Dentistry and Center for Orphaned Autoimmune Disorders (COAD), Gainesville, FL
Background/Purpose: This study was performed to characterize key immune cell subsets and their interactions in patients with childhood Sjögren's disease (cSjD) for the first time…
Abstract Number: 2463 • ACR Convergence 2023
Efficacy and Safety of Car-T-Cell Treatment in Refractory Antisynthetase Syndrome – Data of the First Three Patients
Jule Taubmann¹, Johannes Knitza², Fabian Müller³, Sebastian Boeltz¹, Simon Voelkl⁴, Michael Aigner⁴, Arnd Kleyer⁵, Ioanna Minnopoulou¹, Regina Gary⁴, Sascha kretschmann⁴, Andreas Mackensen⁴ and Georg Schett⁶, ¹Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ²Department of Internal Medicine 3 Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, ³Friedrich Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁴Department of Internal Medicine 5, Hematology and Oncology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ⁵University Hospital Erlangen, Erlangen, Germany, ⁶Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Antisynthetase syndrome (ASS) can be very severe affecting the lungs, the skin and the joints next to the muscles. ASS can take a refractory…
Abstract Number: 0071 • ACR Convergence 2023
Sex Based Differences in Morphological and Functional Niches of the Human Thymus, Identified by Non-supervised Spatial Transcriptomic Profiling, May Underlie Sex Bias in Autoimmune Disease
Viktoria Hennings, Anneke van Dijk, Andri Lemarquis, Christina Lundqvist and Olov Ekwall, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Females exhibit a more robust response to both self- and non-self-antigens than males which manifests as higher prevalence of autoimmune disease, eg. rheumatic diseases,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].